SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No detectable benefit ESCAT >I/II (small size). This ranking could be used in clinics, and amended stepwise when new targets come 1/3
Warming up for
#ESMO22
, online at
@nature
: “Genomics to select treatment for patients with metastatic breast cancer” by
@FAndreMD
and colleagues .
With our brand new
#clinicalbriefing
1
6
29
5
35
135
Replies
implications ?
a. Policy makers: develop clin genomics infrastructures; it has impact on pts
b. MTB: we should refer to ESCAT (or other framework) when making a decision for pts with mBC, but not only to our knowledge in biology
c. Pts: receiving a genomic test is mandatory 2/3
1
2
27
Almost 10 yrs project, very big investment from lot of coll; 1460 pts included, weekly MTB for > 5 yrs
Tks a lot to Institutions and Funders;
@GroupeUnicancer
,
@GustaveRoussy
,
@Inserm
,
@FondationARC
,
@CLCCLeonBerard
,
@BCRFcure
,
@AstraZeneca
,
@Novartis
,
@Institut_cancer
0
1
20
@FAndreMD
Congratulations Fab amazing work - great to see this in print after such a super human effort to make this possible
0
0
2
